lonidamine has been researched along with cytochrome c-t in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maeda, H; Rajesh, KG; Sasaguri, S; Suzuki, R | 1 |
| Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Wang, XX; Zhang, CX; Zhang, L; Zhao, WY; Zhou, J | 1 |
2 other study(ies) available for lonidamine and cytochrome c-t
| Article | Year |
|---|---|
Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antioxidants; Antipyrine; Atractyloside; Blood Pressure; Cytochromes c; DNA Fragmentation; Edaravone; Enzyme Inhibitors; Heart Rate; Indazoles; Male; Mitochondrial Swelling; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Up-Regulation | 2003 |
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; Epirubicin; Female; Humans; Indazoles; Liposomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |